# KLOW Safe — What we know and don't know about the four-peptide KLOW research blend > KLOW combines GHK-Cu, BPC-157, TB-500, and KPV in one vial. No combination study has been published. Here is what the single-agent research actually shows. An evidence-led reading of the four-peptide research blend. Each component has its own literature; the combination has none. Hover any claim to see its source. ## The short version KLOW is a research-peptide blend that ships four distinct compounds in one lyophilized vial: GHK-Cu (50 mg, a copper tripeptide), BPC-157 (10 mg, a 15-residue peptide studied in rodent tissue-repair models), TB-500 (10 mg, the heptapeptide actin-binding fragment of thymosin beta-4), and KPV (10 mg, the anti-inflammatory C-terminal tripeptide of alpha-MSH). None of the four is FDA-approved for systemic human use, and the blend itself has never been tested in any controlled study — in any species. This site is an editorial reading of what the component literature actually shows: what is reasonably well-characterized in animal models, what has limited human data (mostly topical, for GHK-Cu), and what is missing entirely for the combination. It is not a clinic, not a vendor, and not a recommendation. The evidence sits on a spectrum from well-documented rodent findings to theoretical mechanisms to outright unknowns — and this site marks that spectrum at every step. See the [effects page](/effects) for a plain account of what people report and who has reason to be careful. ## What KLOW actually is KLOW is a vendor-formulated research-peptide blend that ships as a single lyophilized vial containing four distinct peptides at a fixed mass ratio. The most common formulation totals 80 mg per vial: 50 mg GHK-Cu (a copper-bound tripeptide), 10 mg BPC-157 (a 15-amino-acid pentadecapeptide), 10 mg TB-500 (a 7-amino-acid fragment of Thymosin Beta-4), and 10 mg KPV (the lysine-proline-valine C-terminal tripeptide of alpha-melanocyte-stimulating hormone) [1]. Each of those four peptides has been the subject of its own preclinical and, in some cases, limited clinical literature. The blend itself has not. No peer-reviewed study has ever characterized the combined administration of all four agents in any species [16]. That distinction is the editorial spine of this site. The four-component KLOW vial is sold as if it were a single research tool, but the safety record we have is a stack of four single-agent records, not a combination record. When this site says 'studied,' it means studied as an individual peptide. When it says 'unknown,' it usually means unknown in the combination, in humans, or both. ## Why a safety-focused reading exists at all Two facts shape the safety conversation around KLOW. First, none of the four components is FDA-approved for systemic human therapeutic use. GHK-Cu is permitted in topical cosmetics, but not for injection. BPC-157 has been classified by the FDA as a Category 2 bulk drug substance — Substances with Safety Concerns — and is explicitly ineligible for pharmacy compounding into human medications [14]. TB-500 is an unapproved investigational compound and is prohibited under WADA category S2 for athletes. KPV has no FDA approval and no published human clinical trial data. Second, the single-agent literature is uneven. BPC-157 has been studied extensively in rats — a 2025 narrative review identified 36 BPC-157 studies, 35 of which were preclinical and only one clinical [5]. GHK-Cu has the strongest human dataset of the four, but almost entirely in topical wound applications [6]. The TB-500 7-amino-acid fragment is frequently conflated with full-length Thymosin Beta-4, which has been studied in Phase 1 and Phase 2 trials [10][11] — but the fragment is not the protein, and clinical safety inferences do not transfer cleanly between them. This site does not tell readers whether to use KLOW. It tells readers what the research record actually says, where the gaps are, and how to read vendor claims against the published evidence. ## What the safety record looks like, briefly **What is reasonably well-characterized in single-agent rodent models:** BPC-157's preclinical toxicology in rats, dogs, rabbits, and guinea pigs identified no minimum toxic dose and no lethal dose, with no genotoxic, teratogenic, anaphylactic, or local toxic effects in single or repeat-dose studies [1]. **What is reasonably well-characterized in topical human use:** GHK-Cu applied as a 2% topical gel to diabetic foot ulcers in a controlled clinical trial improved wound closure by 40% and reduced infection rates by 27% versus standard of care, with no significant safety signal [6]. **What is documented for the full-length Thymosin Beta-4 protein (not the TB-500 fragment) in humans:** A Phase 1 trial of 40 healthy volunteers tested single intravenous doses up to 1260 mg and 14 days of repeat dosing, with no dose-limiting toxicities or serious adverse events [10]. **What is essentially absent:** Any human clinical trial of KPV [13]. Any human safety study of the TB-500 fragment as distinct from full-length Tβ4. Any pharmacokinetic, pharmacology, or safety study of the four peptides administered together [19]. Any long-term (>6 month) data on any component. The full breakdown — component by component, claim by claim — lives on [the research page](/research) and [the safety page](/safety). ## How to read this site Every research finding on this site is tagged with an evidence-quality marker: **HUMAN** when peer-reviewed human clinical data exists for the specific question asked, **PRECLINICAL** when only rodent or in-vitro data exists, and **NO DATA** when no published study addresses the question. The teal/coral color pair carries the same information visually — teal for what is known, coral for what is not. Citations appear inline as bracketed numbers — [1], [2] — and link to the [references page](/references) where every source is listed with its DOI and URL. Hovering any citation on a desktop browser reveals a preview card with the study's title, authors, and finding. The full reference list is grouped by component for easy navigation. This site does not sell anything, does not recommend doses, and is not affiliated with any vendor or laboratory supplier. It is editorial commentary on a body of research — most of it preclinical, much of it incomplete, and none of it sufficient to characterize the four-peptide blend as a combined product in humans. --- Editorial commentary on peer-reviewed research — not a clinic, not a vendor, not a prescription.